Granahan Investment Management LLC Has $6.08 Million Holdings in Xenon Pharmaceuticals Inc. $XENE

Granahan Investment Management LLC increased its position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) by 12.6% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 104,478 shares of the biopharmaceutical company’s stock after acquiring an additional 11,700 shares during the quarter. Granahan Investment Management LLC owned about 0.11% of Xenon Pharmaceuticals worth $6,075,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of XENE. Assenagon Asset Management S.A. acquired a new position in shares of Xenon Pharmaceuticals during the fourth quarter worth approximately $5,342,000. Peregrine Capital Management LLC bought a new stake in shares of Xenon Pharmaceuticals in the fourth quarter valued at approximately $7,837,000. Jennison Associates LLC boosted its position in shares of Xenon Pharmaceuticals by 13.8% in the fourth quarter. Jennison Associates LLC now owns 1,292,055 shares of the biopharmaceutical company’s stock valued at $57,910,000 after acquiring an additional 156,820 shares during the period. NEXTBio Capital Management LP acquired a new stake in shares of Xenon Pharmaceuticals in the fourth quarter worth $8,234,000. Finally, DNB Asset Management AS grew its stake in shares of Xenon Pharmaceuticals by 9.5% in the fourth quarter. DNB Asset Management AS now owns 272,831 shares of the biopharmaceutical company’s stock worth $12,228,000 after acquiring an additional 23,750 shares during the last quarter. Institutional investors and hedge funds own 95.45% of the company’s stock.

Xenon Pharmaceuticals Price Performance

Shares of NASDAQ XENE opened at $65.42 on Friday. Xenon Pharmaceuticals Inc. has a 1-year low of $30.00 and a 1-year high of $72.66. The business has a fifty day moving average price of $58.30 and a 200 day moving average price of $52.62. The stock has a market capitalization of $6.32 billion, a P/E ratio of -13.92 and a beta of 0.61.

Xenon Pharmaceuticals (NASDAQ:XENE) last posted its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported ($1.17) EPS for the quarter, hitting the consensus estimate of ($1.17). During the same quarter in the prior year, the business posted ($0.83) EPS. As a group, equities research analysts anticipate that Xenon Pharmaceuticals Inc. will post -4.92 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research firms recently commented on XENE. Royal Bank Of Canada upped their target price on shares of Xenon Pharmaceuticals from $80.00 to $82.00 and gave the company an “outperform” rating in a research note on Friday, May 8th. Weiss Ratings restated a “sell (d-)” rating on shares of Xenon Pharmaceuticals in a research report on Monday, July 6th. Needham & Company LLC dropped their price objective on shares of Xenon Pharmaceuticals from $80.00 to $78.00 and set a “buy” rating on the stock in a report on Friday, May 8th. Wells Fargo & Company reaffirmed an “overweight” rating and set a $69.00 price objective on shares of Xenon Pharmaceuticals in a research report on Sunday, May 10th. Finally, JPMorgan Chase & Co. increased their target price on shares of Xenon Pharmaceuticals from $80.00 to $82.00 and gave the company an “overweight” rating in a research note on Wednesday, May 27th. Two analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, Xenon Pharmaceuticals currently has an average rating of “Buy” and an average target price of $77.20.

Insider Transactions at Xenon Pharmaceuticals

In other news, Director Gillian Cannon sold 1,190 shares of the company’s stock in a transaction dated Friday, June 5th. The shares were sold at an average price of $53.14, for a total transaction of $63,236.60. Following the transaction, the director owned 1,455 shares in the company, valued at $77,318.70. This represents a 44.99% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Gary Patou sold 1,322 shares of Xenon Pharmaceuticals stock in a transaction that occurred on Friday, June 5th. The stock was sold at an average price of $53.14, for a total transaction of $70,251.08. Following the completion of the sale, the director owned 24,896 shares of the company’s stock, valued at $1,322,973.44. This trade represents a 5.04% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 2.91% of the stock is currently owned by insiders.

About Xenon Pharmaceuticals

Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company’s research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon’s scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company’s pipeline comprises multiple preclinical and clinical programs.